Veracyte Inc.
Pioneering molecular cytology
This article was originally published in Start Up
Executive Summary
Veracyte Inc. aims to reduce ambiguity in cytology samples and thus increase the diagnostic utility of these minimally invasive tests. The first application for its Afirma gene expression classifier is thyroid nodule diagnostics. Studies so far show that it is more than 95% accurate in identifying benign samples among inconclusive cytology results.